年轻扩张型心肌病患者不良结局的临床和超声心动图危险因素

IF 3.4 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Mengwan Li, Wenheng Liu, Shouling Mi, Meng Wang, Yanli Wang, Qilong Guo, Zhexun Lian, Junhua Ge
{"title":"年轻扩张型心肌病患者不良结局的临床和超声心动图危险因素","authors":"Mengwan Li,&nbsp;Wenheng Liu,&nbsp;Shouling Mi,&nbsp;Meng Wang,&nbsp;Yanli Wang,&nbsp;Qilong Guo,&nbsp;Zhexun Lian,&nbsp;Junhua Ge","doi":"10.1155/cdr/2122089","DOIUrl":null,"url":null,"abstract":"<p><b>Purpose:</b> This study is aimed at identifying clinical and echocardiographic factors associated with all-cause mortality or heart transplantation (HTx) in young patients with dilated cardiomyopathy (DCM).</p><p><b>Methods:</b> We conducted a retrospective analysis of hospitalized patients (aged 18–45 years) diagnosed with DCM between January 2012 and December 2022. All patients underwent a 2-year medical therapy for heart failure, followed by at least 1 year of follow-up. Clinical and echocardiographic data were collected at baseline and after the 2-year treatment period. Multivariate Cox proportional hazards regression with a backward stepwise method was used to identify risk factors for all-cause mortality or HTx.</p><p><b>Results:</b> The study cohort comprised 67 patients. Over a median follow-up of 38 months (range 18–50), 15 patients died and 24 underwent HTx. Significant risk factors for all-cause mortality/HTx included smoking, digoxin use, elevated N-terminal pro-brain natriuretic peptide (NT-proBNP, ≥ 5678 pg/mL), higher C-reactive protein (CRP, ≥ 3.0 mg/L), higher uric acid (UA, ≥ 570 <i>μ</i>mol/L), lower left ventricular ejection fraction (LVEF, ≤25%), and enlarged end-diastolic left ventricular diameter (LVD, ≥ 65 mm). Among these, elevated CRP (hazard ratio, HR = 6.727, <i>p</i> &lt; 0.001) and enlarged LVD (HR = 3.038, <i>p</i> = 0.007) were the strongest independent risk factors, irrespective of other risk factors. Moreover, each 5 mm annual increase in end-systolic left atrial diameter (LAD, HR = 3.641, <i>p</i> &lt; 0.001) and each unit annual increase in Ln(NT-proBNP) (HR = 4.069, <i>p</i> &lt; 0.001) were the strongest predictors of all-cause mortality/HTx, even after accounting for the effects of body mass index, duration of treatment, and baseline CRP level.</p><p><b>Conclusions:</b> Intensive monitoring and medical care may be beneficial for young adult DCM patients with defined risk factors such as smoking, elevated NT-proBNP and CRP, lower LVEF, and enlarged LV diameter. Our findings suggest that personalized intensive monitoring and medical care based on identified risk factors may improve outcomes in young adult DCM patients.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/2122089","citationCount":"0","resultStr":"{\"title\":\"Clinical and Echocardiographic Risk Factors of Adverse Outcomes in Young Patients With Dilated Cardiomyopathy\",\"authors\":\"Mengwan Li,&nbsp;Wenheng Liu,&nbsp;Shouling Mi,&nbsp;Meng Wang,&nbsp;Yanli Wang,&nbsp;Qilong Guo,&nbsp;Zhexun Lian,&nbsp;Junhua Ge\",\"doi\":\"10.1155/cdr/2122089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><b>Purpose:</b> This study is aimed at identifying clinical and echocardiographic factors associated with all-cause mortality or heart transplantation (HTx) in young patients with dilated cardiomyopathy (DCM).</p><p><b>Methods:</b> We conducted a retrospective analysis of hospitalized patients (aged 18–45 years) diagnosed with DCM between January 2012 and December 2022. All patients underwent a 2-year medical therapy for heart failure, followed by at least 1 year of follow-up. Clinical and echocardiographic data were collected at baseline and after the 2-year treatment period. Multivariate Cox proportional hazards regression with a backward stepwise method was used to identify risk factors for all-cause mortality or HTx.</p><p><b>Results:</b> The study cohort comprised 67 patients. Over a median follow-up of 38 months (range 18–50), 15 patients died and 24 underwent HTx. Significant risk factors for all-cause mortality/HTx included smoking, digoxin use, elevated N-terminal pro-brain natriuretic peptide (NT-proBNP, ≥ 5678 pg/mL), higher C-reactive protein (CRP, ≥ 3.0 mg/L), higher uric acid (UA, ≥ 570 <i>μ</i>mol/L), lower left ventricular ejection fraction (LVEF, ≤25%), and enlarged end-diastolic left ventricular diameter (LVD, ≥ 65 mm). Among these, elevated CRP (hazard ratio, HR = 6.727, <i>p</i> &lt; 0.001) and enlarged LVD (HR = 3.038, <i>p</i> = 0.007) were the strongest independent risk factors, irrespective of other risk factors. Moreover, each 5 mm annual increase in end-systolic left atrial diameter (LAD, HR = 3.641, <i>p</i> &lt; 0.001) and each unit annual increase in Ln(NT-proBNP) (HR = 4.069, <i>p</i> &lt; 0.001) were the strongest predictors of all-cause mortality/HTx, even after accounting for the effects of body mass index, duration of treatment, and baseline CRP level.</p><p><b>Conclusions:</b> Intensive monitoring and medical care may be beneficial for young adult DCM patients with defined risk factors such as smoking, elevated NT-proBNP and CRP, lower LVEF, and enlarged LV diameter. Our findings suggest that personalized intensive monitoring and medical care based on identified risk factors may improve outcomes in young adult DCM patients.</p>\",\"PeriodicalId\":9582,\"journal\":{\"name\":\"Cardiovascular Therapeutics\",\"volume\":\"2025 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-03-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/2122089\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/cdr/2122089\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/cdr/2122089","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在确定与扩张型心肌病(DCM)年轻患者全因死亡率或心脏移植(HTx)相关的临床和超声心动图因素。方法:回顾性分析2012年1月至2022年12月期间诊断为DCM的住院患者(年龄18-45岁)。所有患者都接受了为期2年的心力衰竭药物治疗,随后进行了至少1年的随访。在基线和2年治疗期后收集临床和超声心动图数据。采用多因素Cox比例风险回归和逆向逐步回归方法来确定全因死亡率或HTx的危险因素。结果:研究队列包括67例患者。中位随访38个月(18-50个月),15例患者死亡,24例患者接受HTx治疗。全因死亡率/HTx的显著危险因素包括吸烟、地高辛使用、n端脑利钠肽前体升高(NT-proBNP,≥5678 pg/mL)、c反应蛋白升高(CRP,≥3.0 mg/L)、尿酸升高(UA,≥570 μmol/L)、左室射血分数降低(LVEF,≤25%)和舒张末期左室直径增大(LVD,≥65 mm)。其中,CRP升高(危险比,HR = 6.727, p <;0.001)和LVD增大(HR = 3.038, p = 0.007)是最强的独立危险因素,与其他危险因素无关。收缩末期左房内径每增加5 mm (LAD, HR = 3.641, p <;0.001)和每单位年Ln(NT-proBNP)的增加(HR = 4.069, p <;0.001)是全因死亡率/HTx的最强预测因子,即使考虑了体重指数、治疗持续时间和基线CRP水平的影响。结论:对于吸烟、NT-proBNP和CRP升高、LVEF降低、左室直径增大等危险因素明确的年轻成年DCM患者,加强监测和医疗护理可能是有益的。我们的研究结果表明,基于确定的危险因素的个性化强化监测和医疗护理可能改善年轻成年DCM患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Clinical and Echocardiographic Risk Factors of Adverse Outcomes in Young Patients With Dilated Cardiomyopathy

Clinical and Echocardiographic Risk Factors of Adverse Outcomes in Young Patients With Dilated Cardiomyopathy

Purpose: This study is aimed at identifying clinical and echocardiographic factors associated with all-cause mortality or heart transplantation (HTx) in young patients with dilated cardiomyopathy (DCM).

Methods: We conducted a retrospective analysis of hospitalized patients (aged 18–45 years) diagnosed with DCM between January 2012 and December 2022. All patients underwent a 2-year medical therapy for heart failure, followed by at least 1 year of follow-up. Clinical and echocardiographic data were collected at baseline and after the 2-year treatment period. Multivariate Cox proportional hazards regression with a backward stepwise method was used to identify risk factors for all-cause mortality or HTx.

Results: The study cohort comprised 67 patients. Over a median follow-up of 38 months (range 18–50), 15 patients died and 24 underwent HTx. Significant risk factors for all-cause mortality/HTx included smoking, digoxin use, elevated N-terminal pro-brain natriuretic peptide (NT-proBNP, ≥ 5678 pg/mL), higher C-reactive protein (CRP, ≥ 3.0 mg/L), higher uric acid (UA, ≥ 570 μmol/L), lower left ventricular ejection fraction (LVEF, ≤25%), and enlarged end-diastolic left ventricular diameter (LVD, ≥ 65 mm). Among these, elevated CRP (hazard ratio, HR = 6.727, p < 0.001) and enlarged LVD (HR = 3.038, p = 0.007) were the strongest independent risk factors, irrespective of other risk factors. Moreover, each 5 mm annual increase in end-systolic left atrial diameter (LAD, HR = 3.641, p < 0.001) and each unit annual increase in Ln(NT-proBNP) (HR = 4.069, p < 0.001) were the strongest predictors of all-cause mortality/HTx, even after accounting for the effects of body mass index, duration of treatment, and baseline CRP level.

Conclusions: Intensive monitoring and medical care may be beneficial for young adult DCM patients with defined risk factors such as smoking, elevated NT-proBNP and CRP, lower LVEF, and enlarged LV diameter. Our findings suggest that personalized intensive monitoring and medical care based on identified risk factors may improve outcomes in young adult DCM patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cardiovascular Therapeutics
Cardiovascular Therapeutics 医学-心血管系统
CiteScore
5.60
自引率
0.00%
发文量
55
审稿时长
6 months
期刊介绍: Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies. Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged. Subject areas include (but are by no means limited to): Acute coronary syndrome Arrhythmias Atherosclerosis Basic cardiac electrophysiology Cardiac catheterization Cardiac remodeling Coagulation and thrombosis Diabetic cardiovascular disease Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF) Hyperlipidemia Hypertension Ischemic heart disease Vascular biology Ventricular assist devices Molecular cardio-biology Myocardial regeneration Lipoprotein metabolism Radial artery access Percutaneous coronary intervention Transcatheter aortic and mitral valve replacement.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信